HARBIN, China, Sept. 20, 2012 /PRNewswire/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) (“China Botanic” or the “Company”), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines (“TCM”) in China, today announced that due to a system error on the Company’s part the conference call scheduled for today, September 20, 2012 was mistakenly cancelled. The management team is rescheduling the conference call and an announcement will be made as soon as possible.
About China Botanic Pharmaceutical Inc.
China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines (“TCM”), in the People’s Republic of China. All of the Company’s products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Company Contact: | CCG Investor Relations: |
China Botanic Pharmaceutical Inc. | Mr. Mark Collinson, Partner |
Ms. Portia Tan, IR Contact | Phone: +1-310-954-1343 (Los Angeles) |
Tel: 86-451-8260-2162 | Email: mark.collinson@ccgir.com |
Email: ir@renhuang.com | Website: www.ccgirasia.com |
SOURCE China Botanic Pharmaceutical Inc.
